XML 135 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt Financing Arrangements
12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Debt Financing Arrangements Debt Financing Arrangements

The Company’s long-term debt consisted of the following:
Debt Instrument
 
 
 
Interest Rate
Face Amount
Due Date
December 31, 2019
 
December 31, 2018
 
 
 
(In millions)
2.5% Notes
$1 billion
2026
$
994

 
$
993

 
 
 
 
 
 
1% Notes
€650 million
2025
723

 
736

 
 
 
 
 
 
1.75% Notes
€600 million
2023
669

 
682

 
 
 
 
 
 
4.5% Notes
$600 million
2049
587

 
587

 
 
 
 
 
 
4.479% Debentures
$516 million
2021
500

 
493

 
 
 
 
 
 
3.75% Notes
$500 million
2047
493

 
493

 
 
 
 
 
 
5.375% Debentures
$470 million
2035
461

 
461

 
 
 
 
 
 
3.375% Notes
$400 million
2022
398

 
398

 
 
 
 
 
 
4.016% Debentures
$570 million
2043
389

 
386

 
 
 
 
 
 
4.535% Debentures
$528 million
2042
384

 
382

 
 
 
 
 
 
5.935% Debentures
$383 million
2032
379

 
378

 
 
 
 
 
 
5.765% Debentures
$378 million
2041
378

 
378

 
 
 
 
 
 
7% Debentures
$164 million
2031
163

 
163

 
 
 
 
 
 
6.625% Debentures
$160 million
2029
159

 
159

 
 
 
 
 
 
6.95% Debentures
$159 million
2097
155

 
155

 
 
 
 
 
 
7.5% Debentures
$150 million
2027
150

 
149

 
 
 
 
 
 
6.45% Debentures
$127 million
2038
126

 
126

 
 
 
 
 
 
6.75% Debentures
$118 million
2027
117

 
117

 
 
 
 
 
 
Floating Rate
€500 million
2019

 
572

 
 
 
 
 
 
Other
 
 
454

 
472

Total long-term debt including current maturities
 
7,679

 
8,280

Current maturities
 
 
(7
)
 
(582
)
Total long-term debt
 
 
$
7,672

 
$
7,698


 
In June 2019, the Company retired €500 million aggregate principal amount of Floating Rate Notes that matured on June 24, 2019.

On December 3, 2018, the Company issued $600 million and $400 million aggregate principal amounts of 4.5% Notes due in 2049 and 3.375% Notes due in 2022, respectively. Net proceeds before expenses for the 4.5% and 3.375% Notes were $588 million and $399 million, respectively.

On September 12, 2018, the Company issued €650 million ($744 million as of December 31, 2018) aggregate principal amount of 1.000% Notes due in 2025. Net proceeds before expenses were $747 million.

Discount amortization expense, net of premium amortization, of $12 million, $10 million, and $11 million for the years ended December 31, 2019, 2018, and 2017, respectively, are included in interest expense related to the Company’s long-term debt.
At December 31, 2019, the fair value of the Company’s long-term debt exceeded the carrying value by $1.5 billion, as estimated using quoted market prices (a Level 2 measurement under applicable accounting standards).

The aggregate maturities of long-term debt for the five years after December 31, 2019, are $7 million, $672 million, $409 million, $678 million, and $48 million, respectively.

At December 31, 2019, the Company had lines of credit, including the accounts receivable securitization programs described below, totaling $9.0 billion, of which $6.4 billion was unused.  The weighted average interest rates on short-term borrowings outstanding at December 31, 2019 and 2018, were 1.23% and 7.95%, respectively.  Of the Company’s total lines of credit, $5.0 billion supported the combined U.S. and European commercial paper borrowing programs, against which there was $1.0 billion of commercial paper outstanding at December 31, 2019.

The Company’s credit facilities and certain debentures require the Company to comply with specified financial and non-financial covenants including maintenance of minimum tangible net worth as well as limitations related to incurring liens, secured debt, and certain other financing arrangements.  The Company is in compliance with these covenants as of December 31, 2019.

The Company had outstanding standby letters of credit and surety bonds at December 31, 2019 and 2018, totaling $1.4 billion and $1.7 billion, respectively.

The Company has accounts receivable securitization programs (the “Programs”).  The Programs provide the Company with up to $1.9 billion in funding resulting from the sale of accounts receivable.  As of December 31, 2019, the Company utilized $1.4 billion of its facility under the Programs (see Note 19 for more information on the Programs).